344 related articles for article (PubMed ID: 23919353)
61. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs.
Hu Y; Bajorath J
J Chem Inf Model; 2010 Dec; 50(12):2112-8. PubMed ID: 21070069
[TBL] [Abstract][Full Text] [Related]
62. Insights into polypharmacology from drug-domain associations.
Moya-García AA; Ranea JA
Bioinformatics; 2013 Aug; 29(16):1934-7. PubMed ID: 23740740
[TBL] [Abstract][Full Text] [Related]
63. LigAdvisor: a versatile and user-friendly web-platform for drug design.
Pinzi L; Tinivella A; Gagliardelli L; Beneventano D; Rastelli G
Nucleic Acids Res; 2021 Jul; 49(W1):W326-W335. PubMed ID: 34023895
[TBL] [Abstract][Full Text] [Related]
64. A simple mathematical approach to the analysis of polypharmacology and polyspecificity data.
Maggiora G; Gokhale V
F1000Res; 2017; 6():. PubMed ID: 28690829
[TBL] [Abstract][Full Text] [Related]
65. Medicinal polypharmacology: Exploration and exploitation of the polypharmacolome in modern drug development.
Stefan SM; Rafehi M
Drug Dev Res; 2024 Feb; 85(1):e22125. PubMed ID: 37920929
[TBL] [Abstract][Full Text] [Related]
66. Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A Computational Perspective.
Janardhan S; Dubovskaja V; Lagunin A; Rao BV; Sastry GN; Poroikov V
Curr Med Chem; 2018; 25(39):5432-5463. PubMed ID: 28969540
[TBL] [Abstract][Full Text] [Related]
67. Identifying Promiscuous Compounds with Activity against Different Target Classes.
Feldmann C; Miljković F; Yonchev D; Bajorath J
Molecules; 2019 Nov; 24(22):. PubMed ID: 31752252
[TBL] [Abstract][Full Text] [Related]
68. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network.
Daminelli S; Haupt VJ; Reimann M; Schroeder M
Integr Biol (Camb); 2012 Jul; 4(7):778-88. PubMed ID: 22538435
[TBL] [Abstract][Full Text] [Related]
69. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space.
Cheng F; Li W; Wu Z; Wang X; Zhang C; Li J; Liu G; Tang Y
J Chem Inf Model; 2013 Apr; 53(4):753-62. PubMed ID: 23527559
[TBL] [Abstract][Full Text] [Related]
70. Drug profiling: knowing where it hits.
Merino A; Bronowska AK; Jackson DB; Cahill DJ
Drug Discov Today; 2010 Sep; 15(17-18):749-56. PubMed ID: 20601095
[TBL] [Abstract][Full Text] [Related]
71. Polypharmacology in a single drug: multitarget drugs.
Bolognesi ML
Curr Med Chem; 2013; 20(13):1639-45. PubMed ID: 23410164
[TBL] [Abstract][Full Text] [Related]
72. Targeting disease, not disease targets: Innovative approaches in tackling neurodegenerative disorders.
Griffioen G
IDrugs; 2007 Apr; 10(4):259-63. PubMed ID: 17390249
[TBL] [Abstract][Full Text] [Related]
73. Conciliating binding efficiency and polypharmacology.
Mestres J; Gregori-Puigjané E
Trends Pharmacol Sci; 2009 Sep; 30(9):470-4. PubMed ID: 19717193
[TBL] [Abstract][Full Text] [Related]
74. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery.
Janga SC; Tzakos A
Mol Biosyst; 2009 Dec; 5(12):1536-48. PubMed ID: 19763339
[TBL] [Abstract][Full Text] [Related]
75. Polypharmacology: promises and new drugs in 2022.
Ryszkiewicz P; Malinowska B; Schlicker E
Pharmacol Rep; 2023 Aug; 75(4):755-770. PubMed ID: 37278927
[TBL] [Abstract][Full Text] [Related]
76. Polypharmacology: drug discovery for the future.
Reddy AS; Zhang S
Expert Rev Clin Pharmacol; 2013 Jan; 6(1):41-7. PubMed ID: 23272792
[TBL] [Abstract][Full Text] [Related]
77. Mining significant substructure pairs for interpreting polypharmacology in drug-target network.
Takigawa I; Tsuda K; Mamitsuka H
PLoS One; 2011 Feb; 6(2):e16999. PubMed ID: 21373195
[TBL] [Abstract][Full Text] [Related]
78. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice.
Liu H; Wang J; Zhou W; Wang Y; Yang L
J Ethnopharmacol; 2013 Apr; 146(3):773-93. PubMed ID: 23415946
[TBL] [Abstract][Full Text] [Related]
79. Creation of a free, Internet-accessible database: the Multiple Target Ligand Database.
Chen C; He Y; Wu J; Zhou J
J Cheminform; 2015; 7():14. PubMed ID: 25897329
[TBL] [Abstract][Full Text] [Related]
80. Modelling bioactivities of combinations of whole extracts of edibles with a simplified theoretical framework reveals the statistical role of molecular diversity and system complexity in their mode of action and their nearly certain safety.
Mayer P
PLoS One; 2020; 15(9):e0239841. PubMed ID: 32986750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
